Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Moon Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
Positioning StanceCONSTRUCTIVE
Market CapAll Cap
Digest Analysis
Quick Take
"Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as a highly mispriced compounder."
Executive Summary
In the Q4 2025 letter, David Moon highlights that despite extensive negative geopolitical and macroeconomic headlines during 2025, stock markets rose because corporate fundamentals remained strong, with S&P 500 earnings growing by roughly 13%. He warns against the psychological trap of short-term extrapolation and notes that market sentiment is highly transitory. Moon Capital Management took advantage of this noise to initiate a high-conviction position in Molina Healthcare (MOH) at ~$160. The firm believes MOH's regulatory Medicaid rate-reset mechanisms will inevitably correct temporary, post-COVID margin pressures, offering a clear path to 2-3x upside and a fair value of up to $675 per share by 2028.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
85%
CautiousHigh
High Conviction (85%)
High-conviction positioning: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Growth Outlook
60%
BearishBullish
Neutral (60%)
Market outlook remains above average conviction: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Risk Appetite
65%
DefensiveAggressive
Balanced (65%)
Risk appetite posture is above average conviction: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Capital Deployment
75%
De-riskingDeploying
Deploying (75%)
Manager actively deployed capital into high-conviction opportunities. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Forward Guidance
50%
CautiousExpansionary
Neutral (50%)
Forward guidance signal: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Language Signal
80%
BearishBullish
Bullish (80%)
Tone analysis indicates high conviction language: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Perceived Risk
45%
Low RiskElevated
Moderate Risk (45%)
Perceived risk level is evaluated as moderate conviction. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Opportunity Density
70%
ScarceAbundant
Abundant (70%)
Opportunity density index indicates above average conviction actionable entry points. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Time Horizon
90%
Short-TermLong-Term
Decade+ (90%)
Investment time horizon reflects a high conviction orientation. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...